{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-24-000022","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.110103+00:00","generated_at":"2026-05-31T14:09:30.836211+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biogen Q2 revenue flat at $2.47B; Non-GAAP EPS up 31% to $5.28; raises FY2024 guidance","bullets":["Q2 total revenue $2,465M flat YoY; GAAP diluted EPS $4.00 (-2%), Non-GAAP diluted EPS $5.28 (+31%).","Core pharma revenue up 5% actual/6% CC; LEQEMBI global in-market sales ~$40M (US ~$30M).","SKYCLARYS rev $100M, ZURZUVAE rev $15M; completed HI-Bio acquisition expanding immunology pipeline.","Raised FY2024 Non-GAAP EPS guidance to $15.75-$16.25 (mid-point ~9% growth vs FY2023).","Retains Biosimilars business; expects operating income growth mid- to high-teen % and margin improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-24-000022","json":"https://secwatch.observer/filing/0000875045-24-000022.json","markdown":"https://secwatch.observer/filing/0000875045-24-000022.md","text":"https://secwatch.observer/filing/0000875045-24-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/0000875045-24-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/biib-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:09:30.836211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}